|Bid||0.3753 x 1000|
|Ask||0.3890 x 2900|
|Day's Range||0.3700 - 0.3890|
|52 Week Range||0.2420 - 1.7500|
|Beta (5Y Monthly)||1.70|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for OCX
Oncocyte Corp. shares rose 5% in premarket trades after the Irvine, Calif., molecular diagnostics company for the detection of cancer, said it would reduce more than 40% of its workforce "to align its team towards key products that address larger markets." As of Dec. 31, 2021, the company employed full-time 110 people, according to Oncocyte's annual report. The positions of Gisela Paulsen, president and chief operating Officer, and Douglas Ross, chief scientific officer, will be eliminated. Onco
Even the best investor on earth makes unsuccessful investments. But serious investors should think long and hard about...
The big shareholder groups in OncoCyte Corporation ( NASDAQ:OCX ) have power over the company. Institutions often own...